In this issue:
- SARS-CoV-2 serology after COVID-19 in pwMS
- Ocrelizumab attenuates antibody responses to SARS-CoV-2 infection
- Personalised extended interval dosing of ocrelizumab during the COVID-19 pandemic
- COVID-19 vaccine hesitancy in pwMS
- 2021 MAGNIMS-CMSC-NAIMS consensus recommendations for MRI in MS
- Impact of common MS symptoms on HRQoL
- aHSCT as a first-line DMT in patients with ‘aggressive’ MS
- A real-world analysis of alemtuzumab vs cladribine for MS
- The impact of childhood tonsillectomy on JCV serological status in pwMS
- De-escalating rituximab dosage in pwMS
Please login below to download this issue (PDF)